BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31427061)

  • 1. Myositis in clinical practice-relevance of new antibodies.
    Moghadam-Kia S; Aggarwal R; Oddis CV
    Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):887-901. PubMed ID: 31427061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.
    Moghadam-Kia S; Aggarwal R; Oddis CV
    Expert Rev Clin Immunol; 2015; 11(11):1265-75. PubMed ID: 26313852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.
    Moghadam-Kia S; Oddis CV; Aggarwal R
    Clin Rev Allergy Immunol; 2017 Feb; 52(1):81-87. PubMed ID: 26767526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the pharmacological treatment of adult myositis.
    Oddis CV
    J Intern Med; 2016 Jul; 280(1):63-74. PubMed ID: 27098592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic advances in myositis.
    Aggarwal R; Oddis CV
    Curr Opin Rheumatol; 2012 Nov; 24(6):635-41. PubMed ID: 22955021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification, diagnosis, and management of idiopathic inflammatory myopathies.
    Lazarou IN; Guerne PA
    J Rheumatol; 2013 May; 40(5):550-64. PubMed ID: 23504386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current diagnosis and treatment of polymyositis and dermatomyositis.
    Sasaki H; Kohsaka H
    Mod Rheumatol; 2018 Nov; 28(6):913-921. PubMed ID: 29669460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
    Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
    Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung Diseases in Inflammatory Myopathies.
    Barba T; Mainbourg S; Nasser M; Lega JC; Cottin V
    Semin Respir Crit Care Med; 2019 Apr; 40(2):255-270. PubMed ID: 31137064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects.
    Mastaglia FL; Garlepp MJ; Phillips BA; Zilko PJ
    Muscle Nerve; 2003 Apr; 27(4):407-25. PubMed ID: 12661042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.
    Love LA; Leff RL; Fraser DD; Targoff IN; Dalakas M; Plotz PH; Miller FW
    Medicine (Baltimore); 1991 Nov; 70(6):360-74. PubMed ID: 1659647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare myositis-specific autoantibody associations among Hungarian patients with idiopathic inflammatory myopathy.
    Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Jobanputra R; Dankó K
    Acta Reumatol Port; 2015; 40(4):337-47. PubMed ID: 26922197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Autoantibody profile in myositis].
    Allenbach Y; Benveniste O
    Rev Med Interne; 2014 Jul; 35(7):437-43. PubMed ID: 24387952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myositis-specific autoantibodies].
    Fujimoto M
    Brain Nerve; 2013 Apr; 65(4):449-60. PubMed ID: 23568993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New insights of myositis-specific and -associated autoantibodies in juvenile and adult type myositis].
    Váncsa A; Dankó K
    Orv Hetil; 2016 Jul; 157(30):1179-84. PubMed ID: 27452067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic strategy in inflammatory myopathies (polymyositis, dermatomyositis, overlap myositis, and immune-mediated necrotizing myopathy)].
    Tournadre A
    Rev Med Interne; 2014 Jul; 35(7):466-71. PubMed ID: 24144868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of myositis autoantibody in patients with idiopathic interstitial lung disease.
    Song JS; Hwang J; Cha HS; Jeong BH; Suh GY; Chung MP; Kang ES
    Yonsei Med J; 2015 May; 56(3):676-83. PubMed ID: 25837172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.
    Krystufková O; Vallerskog T; Helmers SB; Mann H; Putová I; Belácek J; Malmström V; Trollmo C; Vencovsky J; Lundberg IE
    Ann Rheum Dis; 2009 Jun; 68(6):836-43. PubMed ID: 18628284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
    Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.